PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ZOM vs. ALLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ZOM and ALLY is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

ZOM vs. ALLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Zomedica Corp. (ZOM) and Ally Financial Inc. (ALLY). The values are adjusted to include any dividend payments, if applicable.

-25.00%-20.00%-15.00%-10.00%-5.00%0.00%5.00%10.00%SeptemberOctoberNovemberDecember2025February
-19.13%
-3.05%
ZOM
ALLY

Key characteristics

Sharpe Ratio

ZOM:

-0.15

ALLY:

0.18

Sortino Ratio

ZOM:

0.20

ALLY:

0.46

Omega Ratio

ZOM:

1.02

ALLY:

1.07

Calmar Ratio

ZOM:

-0.09

ALLY:

0.17

Martin Ratio

ZOM:

-0.38

ALLY:

0.49

Ulcer Index

ZOM:

23.41%

ALLY:

12.62%

Daily Std Dev

ZOM:

58.51%

ALLY:

33.63%

Max Drawdown

ZOM:

-97.75%

ALLY:

-66.24%

Current Drawdown

ZOM:

-95.93%

ALLY:

-22.87%

Fundamentals

Market Cap

ZOM:

$147.60M

ALLY:

$11.66B

EPS

ZOM:

-$0.06

ALLY:

$1.81

Total Revenue (TTM)

ZOM:

$19.39M

ALLY:

$10.48B

Gross Profit (TTM)

ZOM:

$11.56M

ALLY:

$7.09B

EBITDA (TTM)

ZOM:

-$34.19M

ALLY:

$1.57B

Returns By Period

In the year-to-date period, ZOM achieves a 1.08% return, which is significantly lower than ALLY's 6.83% return.


ZOM

YTD

1.08%

1M

-17.48%

6M

-19.13%

1Y

-2.96%

5Y*

-9.05%

10Y*

N/A

ALLY

YTD

6.83%

1M

7.31%

6M

-3.04%

1Y

10.08%

5Y*

6.61%

10Y*

9.45%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ZOM vs. ALLY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ZOM
The Risk-Adjusted Performance Rank of ZOM is 3838
Overall Rank
The Sharpe Ratio Rank of ZOM is 3838
Sharpe Ratio Rank
The Sortino Ratio Rank of ZOM is 3838
Sortino Ratio Rank
The Omega Ratio Rank of ZOM is 3737
Omega Ratio Rank
The Calmar Ratio Rank of ZOM is 4040
Calmar Ratio Rank
The Martin Ratio Rank of ZOM is 3939
Martin Ratio Rank

ALLY
The Risk-Adjusted Performance Rank of ALLY is 5151
Overall Rank
The Sharpe Ratio Rank of ALLY is 5353
Sharpe Ratio Rank
The Sortino Ratio Rank of ALLY is 4545
Sortino Ratio Rank
The Omega Ratio Rank of ALLY is 4646
Omega Ratio Rank
The Calmar Ratio Rank of ALLY is 5555
Calmar Ratio Rank
The Martin Ratio Rank of ALLY is 5353
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ZOM vs. ALLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Zomedica Corp. (ZOM) and Ally Financial Inc. (ALLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ZOM, currently valued at -0.15, compared to the broader market-2.000.002.004.00-0.150.18
The chart of Sortino ratio for ZOM, currently valued at 0.20, compared to the broader market-4.00-2.000.002.004.000.200.46
The chart of Omega ratio for ZOM, currently valued at 1.02, compared to the broader market0.501.001.502.001.021.07
The chart of Calmar ratio for ZOM, currently valued at -0.09, compared to the broader market0.002.004.006.00-0.090.17
The chart of Martin ratio for ZOM, currently valued at -0.38, compared to the broader market-10.000.0010.0020.0030.00-0.380.49
ZOM
ALLY

The current ZOM Sharpe Ratio is -0.15, which is lower than the ALLY Sharpe Ratio of 0.18. The chart below compares the historical Sharpe Ratios of ZOM and ALLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00SeptemberOctoberNovemberDecember2025February
-0.15
0.18
ZOM
ALLY

Dividends

ZOM vs. ALLY - Dividend Comparison

ZOM has not paid dividends to shareholders, while ALLY's dividend yield for the trailing twelve months is around 3.14%.


TTM202420232022202120202019201820172016
ZOM
Zomedica Corp.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
ALLY
Ally Financial Inc.
3.14%3.33%3.44%4.91%1.85%2.13%2.23%2.47%1.37%0.84%

Drawdowns

ZOM vs. ALLY - Drawdown Comparison

The maximum ZOM drawdown since its inception was -97.75%, which is greater than ALLY's maximum drawdown of -66.24%. Use the drawdown chart below to compare losses from any high point for ZOM and ALLY. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%SeptemberOctoberNovemberDecember2025February
-95.93%
-22.87%
ZOM
ALLY

Volatility

ZOM vs. ALLY - Volatility Comparison

Zomedica Corp. (ZOM) has a higher volatility of 11.38% compared to Ally Financial Inc. (ALLY) at 10.09%. This indicates that ZOM's price experiences larger fluctuations and is considered to be riskier than ALLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%SeptemberOctoberNovemberDecember2025February
11.38%
10.09%
ZOM
ALLY

Financials

ZOM vs. ALLY - Financials Comparison

This section allows you to compare key financial metrics between Zomedica Corp. and Ally Financial Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab